Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.51 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100732 | 0.87 | CYP1A2 (0.76) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL9129561 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 | |
| SCHEMBL29869345 | 0.80 | MEN1 (0.68) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 | |
| SCHEMBL713707 | 0.80 | MEN1 (0.68) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 | |
| SCHEMBL8880802 | 0.79 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL8881283 | 0.79 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 | |
| SCHEMBL16187979 | 0.78 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 | |
| SCHEMBL9132754 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 | |
| SCHEMBL8880899 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 | |
| SCHEMBL6003193 | 0.78 | MEN1 (0.65) | CYP1A2CYP3A4CYP2C9CYP2C19MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420807-B2 | Process for the preparation of quetiapine | FERMION OY (FI) | 2013-04-16 | — | — | US | disclosed |
| EP-2245021-B1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2012-09-12 | — | — | EP | disclosed |
| US-20110112290-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2011-05-12 | — | — | US | disclosed |
| EP-2245021-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | Fermion Oy (FI) | 2010-11-03 | — | — | EP | disclosed |
| CN-1872846-B | Method of preparing 2-benzothiazepines derivative | UBE INDUSTRIES | 2010-06-16 | — | — | CN | disclosed |
| US-7671195-B2 | Process for preparing dibenzothiazepine compounds | ASTRAZENECA UK LIMITED (GB) | 2010-03-02 | — | — | US | disclosed |
| CN-100577653-C | Process for preparing dibenzothiazepine derivatives | UBE INDUSTRIES | 2010-01-06 | — | — | CN | disclosed |
| WO-2009095529-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2009-08-06 | — | — | WO | disclosed |
| CN-101389615-A | Process for preparing dibenzothiazepine compounds | ASTRAZENECA UK LTD UBE IND (GB) | 2009-03-18 | — | — | CN | disclosed |
| EP-1996568-A2 | PROCESS FOR PREPARING DIBENZOTHIAZEPINE COMPOUNDS | AstraZeneca UK Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| CN-1037681-C | Tetrazole derivatives and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 1998-03-11 | — | — | CN | disclosed |
| US-5607929-A | Antiviral dibenzothiazepinone derivatives | GLAXO WELLCOME INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5589474-A | Dibenzothiazepinthione as antiviral agents | GLAXO WELLCOME INC. (US) | 1996-12-31 | — | — | US | disclosed |
| US-5399703-A | Antiallergens | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-03-21 | — | — | US | disclosed |
| EP-0583317-A1 | DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | disclosed |
| EP-0583288-A1 | ANTIVIZAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | disclosed |
| EP-0536400-A1 | TETRAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1993-04-14 | — | — | EP | disclosed |
| WO-1992019607-A1 | DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992019277-A1 | ANTIVIRAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |
| CN-1063687-A | Terazole derivatives and medicine | NIPPON SHINYAKU CO LTD (JP) | 1992-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112290-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE | CYP3A5, QDPR, HTR5A | CYP1A2 34/4885CYP3A4 4/4885CYP2C9 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.